Breaking Finance News

Citigroup announced Acceleron Pharma (NASDAQ:XLRN), upping its target price to $40.00 earlier today

Just yesterday Acceleron Pharma (NASDAQ:XLRN) traded -3.61% lower at $39.58. Acceleron Pharma’s 50-day moving average is $32.79 and its 200-day moving average is $32.08. The last stock price is up 18.92% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 74,412 shares of XLRN traded hands, down from an average trading volume of 264,756

Citigroup upped the price target of Acceleron Pharma (NASDAQ:XLRN) to $40.00 indicating a possible upside of 0.01%.

Previously on 8/19/2016, BTIG Research released a statement about Acceleron Pharma (NASDAQ:XLRN) increased the target price from $0.00 to $46.00. At the time, this indicated a possible upside of 0.49%.

See Chart Below

Acceleron Pharma (NASDAQ:XLRN)

Acceleron Pharma has a 52 week low of $21.93 and a 52 week high of $50.86 The company’s market cap is currently $0.

In addition to Citigroup reporting its target price, a total of 9 firms have reported on the stock. The consensus target price is $47.33 with 4 firms rating the stock a strong buy, 4 firms rating the stock a buy, 0 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.

About Acceleron Pharma (NASDAQ:XLRN)

Acceleron Pharma Inc. is a United States-based clinical stage biopharmaceutical company. The Company focuses on discovering and developing therapies to treat a range of diseases. Its therapeutic candidate, luspatercept, is being evaluated in Phase III studies for the treatment of the hematologic diseases myelodysplastic syndromes (MDS) and beta-thalassemia. Its Sotatercept is an investigational protein therapeutic that manages red blood cell levels by targeting molecules in the transforming growth factor beta (TGF-β) superfamily, which is being evaluated in Phase IIa studies. Its Dalantercept is an investigational protein therapeutic that inhibits angiogenesis by preventing bone morphogenetic proteins 9 (BMP) and BMP10, proteins in the TGF-β superfamily, which is being evaluated in Phase II studies. Its ACE-083 is an investigational protein therapeutic that helps to manage muscle mass and strength in specific muscles and muscle groups, which is being evaluated in Phase I studies.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *